Clinical Trials · NCT03574584
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 37
- Start date
- Jun 2018
- Locations
- 2 sites, United States
- Primary endpoint
- Number of treatment emergent adverse events (TEAEs)